> The CEO of Hollis-Eden Pharmaceuticals, which saw its share price plunge 32 percent on the news the U.S. government would not stockpile its radiation sickness drug, says the real problem may have less to do with the efficacy of the therapy and more to do with politics. Report
> Chutes & Ladders: Gilead Sciences named Norbert W. Bischofberger, PhD. executive vice president, research and development and chief scientific officer and named John F. Milligan, PhD, chief operating officer. Release
> Scolr Pharma will collaborate with BioCryst on the development of an oral version of its flu drug. Report
> Neose Technologies is raising $43 million in a private placement. Release
> You can add Stada Arzneimittel to the list of interested suitors for Merck KGaA's much sought after generic drug business. Report
> Regulators at the FDA have chastised Takeda for failing to outline the risks associated with Rozerem in a TV commercial. Report
> The FDA's new approach to botanicals has spurred research programs. Report
And Finally... Even as doctors tend to discount their ability to influence their patients' harmful lifestyle choices, an estimated 75 percent of the U.S. population relies on the advice of their doctor each year. Report